InnoCare Pharma Limited (INCPF)
InnoCare Pharma Statistics
Share Statistics
InnoCare Pharma has 1.5B shares outstanding. The number of shares has increased by 464.75% in one year.
| Shares Outstanding | 1.5B |
| Shares Change (YoY) | 464.75% |
| Shares Change (QoQ) | -0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 941.09M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -62.53 and the forward PE ratio is null. InnoCare Pharma's PEG ratio is 1.63.
| PE Ratio | -62.53 |
| Forward PE | n/a |
| PS Ratio | 53.45 |
| Forward PS | n/a |
| PB Ratio | 5.52 |
| P/FCF Ratio | -42.63 |
| PEG Ratio | 1.63 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for InnoCare Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.19 |
| Quick Ratio | 4.13 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | -2.61 |
| Debt / FCF | -1.46 |
| Interest Coverage | -18.59 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $678.18K |
| Profits Per Employee | $-579.67K |
| Employee Count | 1,089 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | 1.43M |
| Effective Tax Rate | -0.22% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.11, so InnoCare Pharma's price volatility has been higher than the market average.
| Beta | 1.11 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 3.26 |
| 200-Day Moving Average | 3.26 |
| Relative Strength Index (RSI) | 100 |
| Average Volume (20 Days) | 355 |
Income Statement
In the last 12 months, InnoCare Pharma had revenue of 738.54M and earned -631.26M in profits. Earnings per share was -0.37.
| Revenue | 738.54M |
| Gross Profit | 610.1M |
| Operating Income | -651.15M |
| Net Income | -631.26M |
| EBITDA | -516.55M |
| EBIT | -609.17M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 8.22B in cash and 1.35B in debt, giving a net cash position of 6.88B.
| Cash & Cash Equivalents | 8.22B |
| Total Debt | 1.35B |
| Net Cash | 6.88B |
| Retained Earnings | -5.05B |
| Total Assets | 9.68B |
| Working Capital | 5.96B |
Cash Flow
In the last 12 months, operating cash flow was -671.34M and capital expenditures -254.66M, giving a free cash flow of -926M.
| Operating Cash Flow | -671.34M |
| Capital Expenditures | -254.66M |
| Free Cash Flow | -926M |
| FCF Per Share | -0.54 |
Margins
Gross margin is 82.61%, with operating and profit margins of -88.17% and -85.47%.
| Gross Margin | 82.61% |
| Operating Margin | -88.17% |
| Pretax Margin | -87.23% |
| Profit Margin | -85.47% |
| EBITDA Margin | -69.94% |
| EBIT Margin | -88.17% |
| FCF Margin | -125.38% |
Dividends & Yields
INCPF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for INCPF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 0.92 |
| Piotroski F-Score | 3 |